Treatment and disease-specific survival differences among veterans with Merkel cell carcinoma - 27/06/25
Doi : 10.1016/j.jaad.2025.06.007
Daniel Y. Kim, BS a, b, Linden Huhmann, MS, PhD c, Daniel S. Hippe, MS d, Lee Wheless, MD, PhD e, f, Michelle Pavlis, MD g, h, Jonathan C. Hwang, BS b, i, Mary T. Brophy, MD j, k, Nhan V. Do, MD j, k, Paul Nghiem, MD, PhD d, l, Nathanael Fillmore, PhD a, c, k, m, Rebecca I. Hartman, MD, MPH a, b, n, ⁎ 
a Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
c Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts
d Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington
e Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee
f Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
g Department of Dermatology, Duke University School of Medicine, Durham, North Carolina
h Durham Veterans Affairs Medical Center, Durham, North Carolina
i University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
j Boston University School of Medicine, Boston, Massachusetts
k Department of Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts
l Department of Dermatology, University of Washington, Seattle, Washington
m Dana Farber Cancer Institute, Boston, Massachusetts
n Dermatology Section, VA Integrated Service Network 1 (VISN-1), Jamaica Plain, Massachusetts
∗Correspondence to: Rebecca I. Hartman, MD, MPH, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115Department of DermatologyBrigham and Women's Hospital221 Longwood AveBostonMA02115
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 27 June 2025
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Key words : cutaneous, dermatology, Merkel cell carcinoma, MCC, oncology, SEER, surveillance, epidemiolgy, and end results program, veteran, Veterans Affairs, VA
| Drs Fillmore and Hartman are contributed equally. |
|
| Funding sources: Drs Hartman and Fillmore are supported by the Department of Defense under award number W81XWH2110819. Dr Hartman is also supported by the Department of Veterans Affairs under award number VA CSR&D IK2 CX-002531. Dr Nghiem and Mr Hippe are supported by the National Cancer Institute (P01-CA225517) and the Kelsey Dickson Team Science Courage Research Award in Merkel Cell Carcinoma. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Boston Health Care in Boston, Massachusetts. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Approved by the VA Boston Healthcare System (Protocol #3209). |
© 2025
American Academy of Dermatology, Inc. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?